Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
作者信息
Kim Yeon Jeong, Hong Young Bin, Cho Chi Heum, Seong Yeon-Sun, Bae Insoo
出版信息
Pancreas. 2012 Jul;41(5):804-5. doi: 10.1097/MPA.0b013e31823f3fcb.
Abstract
摘要
相似文献
1
Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.探索蛋白激酶抑制剂：揭示胰腺癌中的吉西他滨耐药性。
Pancreas. 2012 Jul;41(5):804-5. doi: 10.1097/MPA.0b013e31823f3fcb.
2
Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.探索蛋白激酶抑制剂：增强吉西他滨在胰腺癌中的疗效
Pancreas. 2012 Apr;41(3):496-8. doi: 10.1097/MPA.0b013e318230f71a.
3
Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.在复制应激时，需要Wee1来维持ATR/Chk1信号通路。
Oncotarget. 2015 May 30;6(15):13072-87. doi: 10.18632/oncotarget.3865.
4
OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.OSI-027在体外和体内均能抑制胰腺导管腺癌细胞增殖，并增强吉西他滨的治疗效果。
Oncotarget. 2015 Sep 22;6(28):26230-41. doi: 10.18632/oncotarget.4579.
5
In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.吉西他滨与酪氨酸激酶抑制剂联合治疗用多药纳米颗粒的体外研究：联合并非更佳。
Biochimie. 2016 Nov;130:4-13. doi: 10.1016/j.biochi.2016.08.003. Epub 2016 Aug 9.
6
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.抑制 Chk1 可使胰腺癌干细胞对吉西他滨敏感。
Neoplasia. 2012 Jun;14(6):519-25. doi: 10.1593/neo.12538.
7
[Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].[吉西他滨化疗用于晚期或复发胰腺癌患者]
Nihon Rinsho. 2006 Jan;64 Suppl 1:198-202.
8
RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.RC-3095，一种胃泌素释放肽受体拮抗剂，与吉西他滨协同抑制人胰腺癌细胞 CFPAC-1 的体外和体内生长。
Pancreas. 2014 Jan;43(1):15-21. doi: 10.1097/MPA.0b013e3182a714cf.
9
The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.丝裂原活化蛋白激酶激活的蛋白激酶 2 介导胰腺癌细胞对吉西他滨的敏感性。
Cell Cycle. 2014;13(6):884-9. doi: 10.4161/cc.28292. Epub 2014 Feb 21.
10
Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.细胞内KRAS特异性抗体通过诱导内体逃逸增强吉西他滨在胰腺癌中的抗肿瘤疗效。
Cancer Lett. 2021 Jun 1;507:97-111. doi: 10.1016/j.canlet.2021.03.015. Epub 2021 Mar 17.
引用本文的文献
1
Doxycycline potentiates the anti-proliferation effects of gemcitabine in pancreatic cancer cells.强力霉素增强吉西他滨对胰腺癌细胞的抗增殖作用。
Am J Cancer Res. 2021 Jul 15;11(7):3515-3536. eCollection 2021.
2
Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.AKT和MEK通路的双重抑制增强吉非替尼对三阴性乳腺癌细胞的抗癌作用。
Cancers (Basel). 2021 Mar 10;13(6):1205. doi: 10.3390/cancers13061205.
3
ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.癌症及癌症干细胞中的ATM、ATR、CHK1、CHK2和WEE1抑制剂
Medchemcomm. 2016 Nov 30;8(2):295-319. doi: 10.1039/c6md00439c. eCollection 2017 Feb 1.
4
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.达沙替尼与吉西他滨联合使用可降低ALDH1A1的表达，并抑制吉西他滨耐药的胰腺癌MIA PaCa-2细胞的增殖。
Int J Oncol. 2014 Jun;44(6):2132-8. doi: 10.3892/ijo.2014.2357. Epub 2014 Mar 21.
5
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.抑制检查点激酶 2（CHK2）可增强胰腺腺癌细胞对吉西他滨的敏感性。
J Cell Mol Med. 2013 Oct;17(10):1261-70. doi: 10.1111/jcmm.12101. Epub 2013 Jul 16.
本文引用的文献
1
Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.探索蛋白激酶抑制剂：增强吉西他滨在胰腺癌中的疗效
Pancreas. 2012 Apr;41(3):496-8. doi: 10.1097/MPA.0b013e318230f71a.
2
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.极光 B 激酶抑制剂 AZD1152：作用决定因素及增强胰腺癌和结肠癌化疗效果的能力。
Br J Cancer. 2011 Mar 1;104(5):769-80. doi: 10.1038/bjc.2011.21. Epub 2011 Feb 8.
3
Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).在吉西他滨（dFdCyd）耐药的人胰腺细胞中，核苷转运蛋白 2 的质膜定位被打乱。
Cancer Sci. 2011 Mar;102(3):622-9. doi: 10.1111/j.1349-7006.2010.01837.x. Epub 2011 Jan 20.
4
Pancreatic cancer.胰腺癌
N Engl J Med. 2010 Apr 29;362(17):1605-17. doi: 10.1056/NEJMra0901557.
5
Cell cycle kinases as therapeutic targets for cancer.细胞周期激酶作为癌症的治疗靶点。
Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907.
6
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.合成致死性RNA干扰筛选确定胰腺癌中吉西他滨治疗的增敏靶点。
J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43.
7
Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.糖原合酶激酶-3抑制可破坏胰腺癌中的核因子-κB活性，但未能使胰腺癌对吉西他滨化疗敏感。
BMC Cancer. 2009 Apr 30;9:132. doi: 10.1186/1471-2407-9-132.
8
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.药物联合研究中协同作用和拮抗作用的理论基础、实验设计及计算机模拟
Pharmacol Rev. 2006 Sep;58(3):621-81. doi: 10.1124/pr.58.3.10.
9
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.抑制SRC酪氨酸激酶可损害人胰腺腺癌细胞对吉西他滨的固有耐药性和获得性耐药性。
Clin Cancer Res. 2004 Apr 1;10(7):2307-18. doi: 10.1158/1078-0432.ccr-1183-3.
10
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.胰腺癌中活化型AKT的发生率、机制及预后价值
Br J Cancer. 2003 Dec 1;89(11):2110-5. doi: 10.1038/sj.bjc.6601396.
Zotero 插件